Step-down therapy in asthma: A focus on treatment options for patients receiving inhaled corticosteroids and long-acting beta-agonist combination therapy
The management of asthma requires continual reassessment of disease activity and modification of treatment approaches based on the level of asthma control. Among patients receiving combination therapy with inhaled corticosteroids and long-acting beta-agonists (LABAs), asthma guidelines and guidance from the Food and Drug Administration recommend consideration of step-down therapy when asthma control has been achieved. This report reviews the evidence base surrounding medical decision making for patients receiving combination therapy. Several studies have examined the effects of step-down therapy in patients receiving combination therapy. Interpretation of these studies is complicated by lack of confirmation of necessity of combination therapy, varying definitions of asthma control before step-down along with variable durations of asthma control before step-down therapy. Overall, most studies indicate that the discontinuation of LABA after a brief period of asthma control is generally followed by loss of asthma control. The consideration of step-down in asthma medications is an essential component of asthma care over time. However, there are inadequate data at the present time to provide firm guidance as to the optimal step-down approach. Therefore, clinicians will need to balance the benefits and risks associated with these therapies on an individual patient basis as they consider which patients should undergo step-down and which approach would be most appropriate.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Affiliations: Department of Pediatrics, Washington University and St. Louis Children’s Hospital, St. Louis, Missouri, USA
Publication date: January 1, 2012
More about this publication?
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma and by having the potential to directly impact the quality of patient care. AAP welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Allergy Conference (EAC), AAP will publish content from EAC poster sessions as well as review articles derived from EAC lectures.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
- Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Ingenta Connect is not responsible for the content or availability of external websites